+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06887907

Studying Megakaryocytes in Adults with Sickle Cell Disease Including Those at Rest and During Complications

Led by University Hospital, Toulouse · Updated on 2025-03-20

40

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Sickle cell disease is the most common inherited blood disorder worldwide, characterized by chronic hemolysis, inflammation, and complications like vaso-occlusive crises and acute chest syndrome, which cause significant organ damage. This research aims to better understand the role of megakaryocytes, the cells that produce platelets, in sickle cell disease, especially during acute complications. Researchers are studying how these cells may contribute to inflammation and blood clotting in this condition. The study involves collecting blood samples from groups of sickle cell disease patients those stable for at least one year, those stable without crises, and those experiencing acute complications such as vaso-occlusive crisis or acute chest syndrome. The goal is to describe the characteristics and gene activity of circulating megakaryocytes under these different conditions. Participants will provide peripheral blood samples, and researchers will analyze the circulating megakaryocytes over a 12-month period. The main measurement is the detailed description of these cells in the blood. This observational study is led by the University Hospital, Toulouse, and participants will be monitored to help clarify how these cells behave during both stable and crisis phases of sickle cell disease.

CONDITIONS

Brief Title

Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

Research Team

P

Pierre COUGOUL, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here